The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
|Videos|July 20, 2011
Karen Hagemaster on Chemo Documentation Study
Author(s)Karen Hagemaster, RN, BSN
Karen Hagemaster from Advocate Good Samaritan Hospital on Chemotherapy Documentation Study
Advertisement
Karen Hagemaster, RN, BSN, Oncology Services at Advocate Good Samaritan Hospital Talks About the Chemotherapy Documentation Study she was involved in that focused on a verification process for the safe administration of chemotherapy and compliance with hospital policy and regulatory guidelines.
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5